Breast Cancer ICYMI

Key clinical point: Gout, a common inflammatory disease, is associated with a significantly increased risk for subsequent breast cancer (BC) diagnosis, particularly in young women aged ≤50 years.

Major finding: Gout was significantly associated with an increased risk for subsequent BC in the total population (hazard ratio [HR] 1.17; 95% CI 1.05-1.31), with the risk being more prominent among women who were ≤50 years of age (HR 1.58; 95% CI 1.10-2.27).

Study details: Findings are from a retrospective cohort study including 33,799 women with gout and 33,799 women without gout, of which 4.5% and 3.7% of women were diagnosed with BC during the 10 years of follow-up, respectively.

Disclosures: The lead author was supported by the Philipps-University of Marburg and the University Hospital of Giessen and Marburg. The authors declared no conflicts of interest.

Source: Gremke N et al. Association between gout and subsequent breast cancer: A retrospective cohort study including 67,598 primary care patients in Germany. Breast Cancer Res Treat. 2023;199:545-552 (Apr 18). Doi: 10.1007/s10549-023-06944-w

Key clinical point: Gout, a common inflammatory disease, is associated with a significantly increased risk for subsequent breast cancer (BC) diagnosis, particularly in young women aged ≤50 years.

Major finding: Gout was significantly associated with an increased risk for subsequent BC in the total population (hazard ratio [HR] 1.17; 95% CI 1.05-1.31), with the risk being more prominent among women who were ≤50 years of age (HR 1.58; 95% CI 1.10-2.27).

Study details: Findings are from a retrospective cohort study including 33,799 women with gout and 33,799 women without gout, of which 4.5% and 3.7% of women were diagnosed with BC during the 10 years of follow-up, respectively.

Disclosures: The lead author was supported by the Philipps-University of Marburg and the University Hospital of Giessen and Marburg. The authors declared no conflicts of interest.

Source: Gremke N et al. Association between gout and subsequent breast cancer: A retrospective cohort study including 67,598 primary care patients in Germany. Breast Cancer Res Treat. 2023;199:545-552 (Apr 18). Doi: 10.1007/s10549-023-06944-w

Key clinical point: Gout, a common inflammatory disease, is associated with a significantly increased risk for subsequent breast cancer (BC) diagnosis, particularly in young women aged ≤50 years.

Major finding: Gout was significantly associated with an increased risk for subsequent BC in the total population (hazard ratio [HR] 1.17; 95% CI 1.05-1.31), with the risk being more prominent among women who were ≤50 years of age (HR 1.58; 95% CI 1.10-2.27).

Study details: Findings are from a retrospective cohort study including 33,799 women with gout and 33,799 women without gout, of which 4.5% and 3.7% of women were diagnosed with BC during the 10 years of follow-up, respectively.

Disclosures: The lead author was supported by the Philipps-University of Marburg and the University Hospital of Giessen and Marburg. The authors declared no conflicts of interest.

Source: Gremke N et al. Association between gout and subsequent breast cancer: A retrospective cohort study including 67,598 primary care patients in Germany. Breast Cancer Res Treat. 2023;199:545-552 (Apr 18). Doi: 10.1007/s10549-023-06944-w

Key clinical point: Women with lymph-node positive early breast cancer (BC) had a high risk for cancer therapy-related cardiovascular toxicity (CTR-CVT), particularly if they were older or receiving anthracycline treatment.

Major finding: The cumulative incidence of CTR-CVT was 71.8%, with 54.0% of events occurring in patients who were 51-60 years old. Similarly, anthracycline treatment was associated with 51.0% of hypertension, 57.0% of coronary artery disease, 60.0% of heart failure, and 54.0% of atrial fibrillation events.

Study details: Findings are from a retrospective population-based cohort study including 433 women age <60 years with lymph node-positive early BC, of which 53.0%, 18.0%, and 29.0% of women received anthracycline, non-anthracycline-containing chemotherapy, and no chemotherapy, respectively.

Disclosures: This study was supported by the Stockholm County Council and other sources. Three authors declared receiving research funding, payments for traveling and accommodation, or lecture fees from various sources.

Source: Hubbert L et al. Long-term and real-life incidence of cancer therapy-related cardiovascular toxicity in patients with breast cancer: A Swedish cohort study. Front Oncol. 2023;13:1095251 (Apr 19). Doi: 10.3389/fonc.2023.1095251

Key clinical point: Women with lymph-node positive early breast cancer (BC) had a high risk for cancer therapy-related cardiovascular toxicity (CTR-CVT), particularly if they were older or receiving anthracycline treatment.

Major finding: The cumulative incidence of CTR-CVT was 71.8%, with 54.0% of events occurring in patients who were 51-60 years old. Similarly, anthracycline treatment was associated with 51.0% of hypertension, 57.0% of coronary artery disease, 60.0% of heart failure, and 54.0% of atrial fibrillation events.

Study details: Findings are from a retrospective population-based cohort study including 433 women age <60 years with lymph node-positive early BC, of which 53.0%, 18.0%, and 29.0% of women received anthracycline, non-anthracycline-containing chemotherapy, and no chemotherapy, respectively.

Disclosures: This study was supported by the Stockholm County Council and other sources. Three authors declared receiving research funding, payments for traveling and accommodation, or lecture fees from various sources.

Source: Hubbert L et al. Long-term and real-life incidence of cancer therapy-related cardiovascular toxicity in patients with breast cancer: A Swedish cohort study. Front Oncol. 2023;13:1095251 (Apr 19). Doi: 10.3389/fonc.2023.1095251

Key clinical point: Women with lymph-node positive early breast cancer (BC) had a high risk for cancer therapy-related cardiovascular toxicity (CTR-CVT), particularly if they were older or receiving anthracycline treatment.

Major finding: The cumulative incidence of CTR-CVT was 71.8%, with 54.0% of events occurring in patients who were 51-60 years old. Similarly, anthracycline treatment was associated with 51.0% of hypertension, 57.0% of coronary artery disease, 60.0% of heart failure, and 54.0% of atrial fibrillation events.

Study details: Findings are from a retrospective population-based cohort study including 433 women age <60 years with lymph node-positive early BC, of which 53.0%, 18.0%, and 29.0% of women received anthracycline, non-anthracycline-containing chemotherapy, and no chemotherapy, respectively.

Disclosures: This study was supported by the Stockholm County Council and other sources. Three authors declared receiving research funding, payments for traveling and accommodation, or lecture fees from various sources.

Source: Hubbert L et al. Long-term and real-life incidence of cancer therapy-related cardiovascular toxicity in patients with breast cancer: A Swedish cohort study. Front Oncol. 2023;13:1095251 (Apr 19). Doi: 10.3389/fonc.2023.1095251

Key clinical point: Presence of depression before and after the diagnosis of breast cancer (BC) was associated with worsened survival outcomes in women with primary invasive BC.

Major finding: Compared with patients without depression, survival was worse among patients who had depression either before (hazard ratio [HR] 1.38; P = .007) or after (HR 1.48; P < .001) BC diagnosis but not among patients with persistent depression.

Study details: Findings are from an analysis of 6054 women with primary invasive BC from the Kentucky Cancer Registry, of which 3.7%, 6.0%, and 4.1% of patients had pre‐diagnosis depression only, post‐diagnosis depression only, and persistent depression, respectively.

Disclosures: This study was funded by US Centers for Disease Control and Prevention and other sources. Two authors declared receiving fees or grant funding from the funding agencies and other sources.

Source: Lei F et al. Influence of depression on breast cancer treatment and survival: A Kentucky population-based study. Cancer. 2023 (Apr 17). Doi: 10.1002/cncr.34676

Key clinical point: Presence of depression before and after the diagnosis of breast cancer (BC) was associated with worsened survival outcomes in women with primary invasive BC.

Major finding: Compared with patients without depression, survival was worse among patients who had depression either before (hazard ratio [HR] 1.38; P = .007) or after (HR 1.48; P < .001) BC diagnosis but not among patients with persistent depression.

Study details: Findings are from an analysis of 6054 women with primary invasive BC from the Kentucky Cancer Registry, of which 3.7%, 6.0%, and 4.1% of patients had pre‐diagnosis depression only, post‐diagnosis depression only, and persistent depression, respectively.

Disclosures: This study was funded by US Centers for Disease Control and Prevention and other sources. Two authors declared receiving fees or grant funding from the funding agencies and other sources.

Source: Lei F et al. Influence of depression on breast cancer treatment and survival: A Kentucky population-based study. Cancer. 2023 (Apr 17). Doi: 10.1002/cncr.34676

Key clinical point: Presence of depression before and after the diagnosis of breast cancer (BC) was associated with worsened survival outcomes in women with primary invasive BC.

Major finding: Compared with patients without depression, survival was worse among patients who had depression either before (hazard ratio [HR] 1.38; P = .007) or after (HR 1.48; P < .001) BC diagnosis but not among patients with persistent depression.

Study details: Findings are from an analysis of 6054 women with primary invasive BC from the Kentucky Cancer Registry, of which 3.7%, 6.0%, and 4.1% of patients had pre‐diagnosis depression only, post‐diagnosis depression only, and persistent depression, respectively.

Disclosures: This study was funded by US Centers for Disease Control and Prevention and other sources. Two authors declared receiving fees or grant funding from the funding agencies and other sources.

Source: Lei F et al. Influence of depression on breast cancer treatment and survival: A Kentucky population-based study. Cancer. 2023 (Apr 17). Doi: 10.1002/cncr.34676

Key clinical point: Germline pathogenic variants (PV) in genes other than BRCA1/2, such as ATM and PALB2, are associated with an increased risk for breast cancer (BC) in men.

Major finding: A higher proportion of males with vs without BC had PV in genes other than BRCA1/2 (4.8% vs 1.8%). Overall, PV in genes other than BRCA1/2 were associated with a >3-fold increased risk for BC (odds ratio [OR] 3.48; P < .0001), with the risk being even higher with PV in PALB2 (OR 7.28; P = .034) and ATM (OR 4.79; P = .035) genes.

Study details: Findings are from a retrospective, case-control study including 767 males with BC who were BRCA1/2-negative and 1349 male control individuals without a personal history of cancer.

Disclosures: This study was supported by Associazione Italiana Ricerca Cancro and other sources. The authors declared no conflicts of interest.

Source: Bucalo A et al. Male breast cancer risk associated with pathogenic variants in genes other than BRCA1/2: An Italian case-control study. Eur J Cancer. 2023 (May 2). Doi: 10.1016/j.ejca.2023.04.022

Key clinical point: Germline pathogenic variants (PV) in genes other than BRCA1/2, such as ATM and PALB2, are associated with an increased risk for breast cancer (BC) in men.

Major finding: A higher proportion of males with vs without BC had PV in genes other than BRCA1/2 (4.8% vs 1.8%). Overall, PV in genes other than BRCA1/2 were associated with a >3-fold increased risk for BC (odds ratio [OR] 3.48; P < .0001), with the risk being even higher with PV in PALB2 (OR 7.28; P = .034) and ATM (OR 4.79; P = .035) genes.

Study details: Findings are from a retrospective, case-control study including 767 males with BC who were BRCA1/2-negative and 1349 male control individuals without a personal history of cancer.

Disclosures: This study was supported by Associazione Italiana Ricerca Cancro and other sources. The authors declared no conflicts of interest.

Source: Bucalo A et al. Male breast cancer risk associated with pathogenic variants in genes other than BRCA1/2: An Italian case-control study. Eur J Cancer. 2023 (May 2). Doi: 10.1016/j.ejca.2023.04.022

Key clinical point: Germline pathogenic variants (PV) in genes other than BRCA1/2, such as ATM and PALB2, are associated with an increased risk for breast cancer (BC) in men.

Major finding: A higher proportion of males with vs without BC had PV in genes other than BRCA1/2 (4.8% vs 1.8%). Overall, PV in genes other than BRCA1/2 were associated with a >3-fold increased risk for BC (odds ratio [OR] 3.48; P < .0001), with the risk being even higher with PV in PALB2 (OR 7.28; P = .034) and ATM (OR 4.79; P = .035) genes.

Study details: Findings are from a retrospective, case-control study including 767 males with BC who were BRCA1/2-negative and 1349 male control individuals without a personal history of cancer.

Disclosures: This study was supported by Associazione Italiana Ricerca Cancro and other sources. The authors declared no conflicts of interest.

Source: Bucalo A et al. Male breast cancer risk associated with pathogenic variants in genes other than BRCA1/2: An Italian case-control study. Eur J Cancer. 2023 (May 2). Doi: 10.1016/j.ejca.2023.04.022

Key clinical point: Chemotherapy plus endocrine therapy (CET) was more effective than endocrine therapy (ET) alone in improving overall survival (OS) outcomes in patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer (BC) and a recurrence score (RS) of 20-25.

Major finding: Although OS was significantly inferior in patients with RS of >20 (P < .001-.019), CET vs ET improved OS in patients with RS of 20-25 regardless of age (age ≤50: hazard ratio [HR] 0.334; P = .002 and age >50: HR 0.521; P = .019).

Study details: This retrospective cohort study of real-world data from the US National Cancer Database included 28,427 women with stage I-III HR+/HER2− BC and 1-3 positive axillary lymph nodes, of which 26.3% and 73.7% of patients received CET and ET, respectively.

Disclosures: The lead author is supported by the Sociedade Beneficente Israelita Brasileira Albert Einstein. The authors declared no conflicts of interest.

Source: Stabellini N et al. Adjuvant chemotherapy is associated with an overall survival benefit regardless of age in ER+/HER2- breast cancer pts with 1-3 positive nodes and oncotype DX recurrence score 20 to 25: An NCDB analysis. Front Oncol. 2023;13:1115208 (Apr 24). Doi: 10.3389/fonc.2023.1115208

Key clinical point: Chemotherapy plus endocrine therapy (CET) was more effective than endocrine therapy (ET) alone in improving overall survival (OS) outcomes in patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer (BC) and a recurrence score (RS) of 20-25.

Major finding: Although OS was significantly inferior in patients with RS of >20 (P < .001-.019), CET vs ET improved OS in patients with RS of 20-25 regardless of age (age ≤50: hazard ratio [HR] 0.334; P = .002 and age >50: HR 0.521; P = .019).

Study details: This retrospective cohort study of real-world data from the US National Cancer Database included 28,427 women with stage I-III HR+/HER2− BC and 1-3 positive axillary lymph nodes, of which 26.3% and 73.7% of patients received CET and ET, respectively.

Disclosures: The lead author is supported by the Sociedade Beneficente Israelita Brasileira Albert Einstein. The authors declared no conflicts of interest.

Source: Stabellini N et al. Adjuvant chemotherapy is associated with an overall survival benefit regardless of age in ER+/HER2- breast cancer pts with 1-3 positive nodes and oncotype DX recurrence score 20 to 25: An NCDB analysis. Front Oncol. 2023;13:1115208 (Apr 24). Doi: 10.3389/fonc.2023.1115208

Key clinical point: Chemotherapy plus endocrine therapy (CET) was more effective than endocrine therapy (ET) alone in improving overall survival (OS) outcomes in patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer (BC) and a recurrence score (RS) of 20-25.

Major finding: Although OS was significantly inferior in patients with RS of >20 (P < .001-.019), CET vs ET improved OS in patients with RS of 20-25 regardless of age (age ≤50: hazard ratio [HR] 0.334; P = .002 and age >50: HR 0.521; P = .019).

Study details: This retrospective cohort study of real-world data from the US National Cancer Database included 28,427 women with stage I-III HR+/HER2− BC and 1-3 positive axillary lymph nodes, of which 26.3% and 73.7% of patients received CET and ET, respectively.

Disclosures: The lead author is supported by the Sociedade Beneficente Israelita Brasileira Albert Einstein. The authors declared no conflicts of interest.

Source: Stabellini N et al. Adjuvant chemotherapy is associated with an overall survival benefit regardless of age in ER+/HER2- breast cancer pts with 1-3 positive nodes and oncotype DX recurrence score 20 to 25: An NCDB analysis. Front Oncol. 2023;13:1115208 (Apr 24). Doi: 10.3389/fonc.2023.1115208

Key clinical point: In postmenopausal women with hormone receptor-positive (HR+) early-stage breast cancer (BC), extending anastrozole treatment for an additional 5 years after initial 5-year treatment with anastrozole-containing hormone therapy improved disease-free survival (DFS) without any major adverse event occurrence.

Major finding: Continuation of anastrozole treatment for an additional 5 years significantly improved 5-year DFS (hazard ratio [HR] 0.62; P = .0010). The incidence of grade ≥3 adverse events was <1% in both groups, with no significant difference observed between both the groups.

Study details: Findings are from the phase 3, AERAS trial including 1593 postmenopausal women with HR+ early-stage invasive BC who were disease-free at 5 years after postoperative endocrine therapy and were randomly assigned to stop or continue receiving anastrozole for an additional 5 years.

Disclosures: This study was supported by Public Health Research Foundation, Japan. Several authors declared receiving honoraria or research funding or serving on speaker’s bureaus, in consulting roles, or in advisory roles for various sources.

Source: Iwase T et al. Postoperative adjuvant anastrozole for 10 or 5 Years in patients with hormone receptor-positive breast cancer: AERAS, a randomized multicenter open-label phase III trial. J Clin Oncol. 2023 (Apr 20). Doi: 10.1200/JCO.22.00577

Key clinical point: In postmenopausal women with hormone receptor-positive (HR+) early-stage breast cancer (BC), extending anastrozole treatment for an additional 5 years after initial 5-year treatment with anastrozole-containing hormone therapy improved disease-free survival (DFS) without any major adverse event occurrence.

Major finding: Continuation of anastrozole treatment for an additional 5 years significantly improved 5-year DFS (hazard ratio [HR] 0.62; P = .0010). The incidence of grade ≥3 adverse events was <1% in both groups, with no significant difference observed between both the groups.

Study details: Findings are from the phase 3, AERAS trial including 1593 postmenopausal women with HR+ early-stage invasive BC who were disease-free at 5 years after postoperative endocrine therapy and were randomly assigned to stop or continue receiving anastrozole for an additional 5 years.

Disclosures: This study was supported by Public Health Research Foundation, Japan. Several authors declared receiving honoraria or research funding or serving on speaker’s bureaus, in consulting roles, or in advisory roles for various sources.

Source: Iwase T et al. Postoperative adjuvant anastrozole for 10 or 5 Years in patients with hormone receptor-positive breast cancer: AERAS, a randomized multicenter open-label phase III trial. J Clin Oncol. 2023 (Apr 20). Doi: 10.1200/JCO.22.00577

Key clinical point: In postmenopausal women with hormone receptor-positive (HR+) early-stage breast cancer (BC), extending anastrozole treatment for an additional 5 years after initial 5-year treatment with anastrozole-containing hormone therapy improved disease-free survival (DFS) without any major adverse event occurrence.

Major finding: Continuation of anastrozole treatment for an additional 5 years significantly improved 5-year DFS (hazard ratio [HR] 0.62; P = .0010). The incidence of grade ≥3 adverse events was <1% in both groups, with no significant difference observed between both the groups.

Study details: Findings are from the phase 3, AERAS trial including 1593 postmenopausal women with HR+ early-stage invasive BC who were disease-free at 5 years after postoperative endocrine therapy and were randomly assigned to stop or continue receiving anastrozole for an additional 5 years.

Disclosures: This study was supported by Public Health Research Foundation, Japan. Several authors declared receiving honoraria or research funding or serving on speaker’s bureaus, in consulting roles, or in advisory roles for various sources.

Source: Iwase T et al. Postoperative adjuvant anastrozole for 10 or 5 Years in patients with hormone receptor-positive breast cancer: AERAS, a randomized multicenter open-label phase III trial. J Clin Oncol. 2023 (Apr 20). Doi: 10.1200/JCO.22.00577

Key clinical point: Pathologic complete response (pCR) rate was higher in patients with high-risk hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer (BC) who received neoadjuvant nanoparticle albumin-bound (nab)-paclitaxel vs solvent-based (sb)-paclitaxel.

Major finding: The pCR rate was higher in the overall population receiving nab-paclitaxel vs sb-paclitaxel (20.8% vs 12.9%; P = .002), subgroups with recurrence score of >25 vs ≤25 (16.0% vs 8.4%; P = .021), and endocrine therapy non-responders vs responders (15.1% vs 6.0%; P = .027). Distant disease-free survival was longer in patients who achieved pCR (hazard ratio 0.42; P = .024).

Study details: Findings are from the WSG-ADAPT trial including 864 patients with high-risk HR+/HER2− early BC who were randomly assigned to receive neoadjuvant sb-paclitaxel or nab-paclitaxel, both followed by epirubicin+cyclophosphamide.

Disclosures: This study was supported by Exact Science, Celgene, Amgen, and AOK Rheinland/Hamburg. Some authors declared receiving consulting fees, honoraria, payment, research funding, or travel support, or having other ties with several sources.

Source: Gluz O et al. Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2- early breast cancer: Results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2- trial. Ann Oncol. 2023 (Apr 14). Doi: 10.1016/j.annonc.2023.04.002

Key clinical point: Pathologic complete response (pCR) rate was higher in patients with high-risk hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer (BC) who received neoadjuvant nanoparticle albumin-bound (nab)-paclitaxel vs solvent-based (sb)-paclitaxel.

Major finding: The pCR rate was higher in the overall population receiving nab-paclitaxel vs sb-paclitaxel (20.8% vs 12.9%; P = .002), subgroups with recurrence score of >25 vs ≤25 (16.0% vs 8.4%; P = .021), and endocrine therapy non-responders vs responders (15.1% vs 6.0%; P = .027). Distant disease-free survival was longer in patients who achieved pCR (hazard ratio 0.42; P = .024).

Study details: Findings are from the WSG-ADAPT trial including 864 patients with high-risk HR+/HER2− early BC who were randomly assigned to receive neoadjuvant sb-paclitaxel or nab-paclitaxel, both followed by epirubicin+cyclophosphamide.

Disclosures: This study was supported by Exact Science, Celgene, Amgen, and AOK Rheinland/Hamburg. Some authors declared receiving consulting fees, honoraria, payment, research funding, or travel support, or having other ties with several sources.

Source: Gluz O et al. Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2- early breast cancer: Results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2- trial. Ann Oncol. 2023 (Apr 14). Doi: 10.1016/j.annonc.2023.04.002

Key clinical point: Pathologic complete response (pCR) rate was higher in patients with high-risk hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer (BC) who received neoadjuvant nanoparticle albumin-bound (nab)-paclitaxel vs solvent-based (sb)-paclitaxel.

Major finding: The pCR rate was higher in the overall population receiving nab-paclitaxel vs sb-paclitaxel (20.8% vs 12.9%; P = .002), subgroups with recurrence score of >25 vs ≤25 (16.0% vs 8.4%; P = .021), and endocrine therapy non-responders vs responders (15.1% vs 6.0%; P = .027). Distant disease-free survival was longer in patients who achieved pCR (hazard ratio 0.42; P = .024).

Study details: Findings are from the WSG-ADAPT trial including 864 patients with high-risk HR+/HER2− early BC who were randomly assigned to receive neoadjuvant sb-paclitaxel or nab-paclitaxel, both followed by epirubicin+cyclophosphamide.

Disclosures: This study was supported by Exact Science, Celgene, Amgen, and AOK Rheinland/Hamburg. Some authors declared receiving consulting fees, honoraria, payment, research funding, or travel support, or having other ties with several sources.

Source: Gluz O et al. Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2- early breast cancer: Results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2- trial. Ann Oncol. 2023 (Apr 14). Doi: 10.1016/j.annonc.2023.04.002

Key clinical point: Survival outcomes were worsened in women with triple-negative breast cancer (TNBC) who were prescribed monthly antibiotics after TNBC diagnosis.

Major finding: Each additional total and unique monthly antimicrobial prescription was associated with inferior breast cancer-specific survival (hazard ratio [HR] 1.05; 95% CI 1.01-1.08, and HR 1.18; 95% CI 1.13-1.24, respectively) and overall survival (HR 1.05; 95% CI 1.02-1.08, and HR 1.17; 95% CI 1.12-1.23, respectively), with the association sustaining through the third year after TNBC diagnosis.

Study details: This study analyzed the data of 772 women with stage I-III TNBC from the Oncoshare database (including integrated data of electronic medical records and California Cancer Registry) who were treated with or without standard cytotoxic chemotherapy, of which 654 women received antibiotics.

Disclosures: This study was supported by the Breast Cancer Research Foundation, New York, and other sources. The authors declared no conflicts of interest.

Source: Ransohoff JD et al. Antimicrobial exposure is associated with decreased survival in triple-negative breast cancer. Nat Commun. 2023;14:2053 (Apr 12). Doi: 10.1038/s41467-023-37636-0

Key clinical point: Survival outcomes were worsened in women with triple-negative breast cancer (TNBC) who were prescribed monthly antibiotics after TNBC diagnosis.

Major finding: Each additional total and unique monthly antimicrobial prescription was associated with inferior breast cancer-specific survival (hazard ratio [HR] 1.05; 95% CI 1.01-1.08, and HR 1.18; 95% CI 1.13-1.24, respectively) and overall survival (HR 1.05; 95% CI 1.02-1.08, and HR 1.17; 95% CI 1.12-1.23, respectively), with the association sustaining through the third year after TNBC diagnosis.

Study details: This study analyzed the data of 772 women with stage I-III TNBC from the Oncoshare database (including integrated data of electronic medical records and California Cancer Registry) who were treated with or without standard cytotoxic chemotherapy, of which 654 women received antibiotics.

Disclosures: This study was supported by the Breast Cancer Research Foundation, New York, and other sources. The authors declared no conflicts of interest.

Source: Ransohoff JD et al. Antimicrobial exposure is associated with decreased survival in triple-negative breast cancer. Nat Commun. 2023;14:2053 (Apr 12). Doi: 10.1038/s41467-023-37636-0

Key clinical point: Survival outcomes were worsened in women with triple-negative breast cancer (TNBC) who were prescribed monthly antibiotics after TNBC diagnosis.

Major finding: Each additional total and unique monthly antimicrobial prescription was associated with inferior breast cancer-specific survival (hazard ratio [HR] 1.05; 95% CI 1.01-1.08, and HR 1.18; 95% CI 1.13-1.24, respectively) and overall survival (HR 1.05; 95% CI 1.02-1.08, and HR 1.17; 95% CI 1.12-1.23, respectively), with the association sustaining through the third year after TNBC diagnosis.

Study details: This study analyzed the data of 772 women with stage I-III TNBC from the Oncoshare database (including integrated data of electronic medical records and California Cancer Registry) who were treated with or without standard cytotoxic chemotherapy, of which 654 women received antibiotics.

Disclosures: This study was supported by the Breast Cancer Research Foundation, New York, and other sources. The authors declared no conflicts of interest.

Source: Ransohoff JD et al. Antimicrobial exposure is associated with decreased survival in triple-negative breast cancer. Nat Commun. 2023;14:2053 (Apr 12). Doi: 10.1038/s41467-023-37636-0

Key clinical point: Women who developed breast cancer (BC) showed a significantly slower rate of decrease in mammographic breast density over time compared with control individuals who did not develop BC.

Major finding: Although breast density decreased over time in all women, the rate of change in breast density was significantly slower in the breast that later developed cancer compared with the cancer-free breast in control individuals (estimate 0.027; P = .04).

Study details: This prospective, nested case-control cohort study followed women with no history of any cancer for 10 years based on screening mammogram or risk factors and subsequently analyzed 289 women who developed BC and 658 matched control individuals.

Disclosures: This study was supported by grants from the Breast Cancer Research Foundation, New York (BCRF) and partly by the US National Cancer Institute (NCI). Two authors declared receiving grants from BCRF and NCI and holding a pending patent for assessment of digital mammograms.

Source: Jiang S et al. Longitudinal analysis of change in mammographic density in each breast and its association with breast cancer risk. JAMA Oncol. 2023 (Apr 27). Doi: 10.1001/jamaoncol.2023.0434

Key clinical point: Women who developed breast cancer (BC) showed a significantly slower rate of decrease in mammographic breast density over time compared with control individuals who did not develop BC.

Major finding: Although breast density decreased over time in all women, the rate of change in breast density was significantly slower in the breast that later developed cancer compared with the cancer-free breast in control individuals (estimate 0.027; P = .04).

Study details: This prospective, nested case-control cohort study followed women with no history of any cancer for 10 years based on screening mammogram or risk factors and subsequently analyzed 289 women who developed BC and 658 matched control individuals.

Disclosures: This study was supported by grants from the Breast Cancer Research Foundation, New York (BCRF) and partly by the US National Cancer Institute (NCI). Two authors declared receiving grants from BCRF and NCI and holding a pending patent for assessment of digital mammograms.

Source: Jiang S et al. Longitudinal analysis of change in mammographic density in each breast and its association with breast cancer risk. JAMA Oncol. 2023 (Apr 27). Doi: 10.1001/jamaoncol.2023.0434

Key clinical point: Women who developed breast cancer (BC) showed a significantly slower rate of decrease in mammographic breast density over time compared with control individuals who did not develop BC.

Major finding: Although breast density decreased over time in all women, the rate of change in breast density was significantly slower in the breast that later developed cancer compared with the cancer-free breast in control individuals (estimate 0.027; P = .04).

Study details: This prospective, nested case-control cohort study followed women with no history of any cancer for 10 years based on screening mammogram or risk factors and subsequently analyzed 289 women who developed BC and 658 matched control individuals.

Disclosures: This study was supported by grants from the Breast Cancer Research Foundation, New York (BCRF) and partly by the US National Cancer Institute (NCI). Two authors declared receiving grants from BCRF and NCI and holding a pending patent for assessment of digital mammograms.

Source: Jiang S et al. Longitudinal analysis of change in mammographic density in each breast and its association with breast cancer risk. JAMA Oncol. 2023 (Apr 27). Doi: 10.1001/jamaoncol.2023.0434

Key clinical point: Trastuzumab deruxtecan demonstrated a favorable benefit-risk profile in patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) who were refractory or resistant to trastuzumab emtansine and had scarce treatment options.

Major finding: The median progression-free survival was significantly prolonged in the trastuzumab deruxtecan vs physician’s choice treatment group (17.8 vs 6.9 months; hazard ratio 0.36; P < .0001). No new safety signals were reported for trastuzumab deruxtecan.

Study details: Findings are from the phase 3, DESTINY-Breast02 trial including 608 patients with HER2+ metastatic BC who were refractory or resistant to trastuzumab emtansine and were randomly assigned to receive trastuzumab deruxtecan or treatment of physician's choice.

Disclosures: This study was funded by Daiichi Sankyo and AstraZeneca. Five authors declared being current or former employees of Daichi Sankyo, and two authors declared owning stock options in AstraZeneca or Daiichi Sankyo. The other authors reported ties with several sources.

Source: Andre F et al. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): A randomised, open-label, multicentre, phase 3 trial. Lancet. 2023 (Apr 19). Doi: 10.1016/S0140-6736(23)00725-0

Key clinical point: Trastuzumab deruxtecan demonstrated a favorable benefit-risk profile in patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) who were refractory or resistant to trastuzumab emtansine and had scarce treatment options.

Major finding: The median progression-free survival was significantly prolonged in the trastuzumab deruxtecan vs physician’s choice treatment group (17.8 vs 6.9 months; hazard ratio 0.36; P < .0001). No new safety signals were reported for trastuzumab deruxtecan.

Study details: Findings are from the phase 3, DESTINY-Breast02 trial including 608 patients with HER2+ metastatic BC who were refractory or resistant to trastuzumab emtansine and were randomly assigned to receive trastuzumab deruxtecan or treatment of physician's choice.

Disclosures: This study was funded by Daiichi Sankyo and AstraZeneca. Five authors declared being current or former employees of Daichi Sankyo, and two authors declared owning stock options in AstraZeneca or Daiichi Sankyo. The other authors reported ties with several sources.

Source: Andre F et al. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): A randomised, open-label, multicentre, phase 3 trial. Lancet. 2023 (Apr 19). Doi: 10.1016/S0140-6736(23)00725-0

Key clinical point: Trastuzumab deruxtecan demonstrated a favorable benefit-risk profile in patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) who were refractory or resistant to trastuzumab emtansine and had scarce treatment options.

Major finding: The median progression-free survival was significantly prolonged in the trastuzumab deruxtecan vs physician’s choice treatment group (17.8 vs 6.9 months; hazard ratio 0.36; P < .0001). No new safety signals were reported for trastuzumab deruxtecan.

Study details: Findings are from the phase 3, DESTINY-Breast02 trial including 608 patients with HER2+ metastatic BC who were refractory or resistant to trastuzumab emtansine and were randomly assigned to receive trastuzumab deruxtecan or treatment of physician's choice.

Disclosures: This study was funded by Daiichi Sankyo and AstraZeneca. Five authors declared being current or former employees of Daichi Sankyo, and two authors declared owning stock options in AstraZeneca or Daiichi Sankyo. The other authors reported ties with several sources.

Source: Andre F et al. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): A randomised, open-label, multicentre, phase 3 trial. Lancet. 2023 (Apr 19). Doi: 10.1016/S0140-6736(23)00725-0